LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

46.92 -2.72

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

46.92

Max

48.27

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -2.3M
Pārdošana	-3.9M 208M
P/E Sektora vidējais	48.435 50.102
EPS	0.21
Peļņas marža	-1.104
Darbinieki	778
EBITDA	-72M 19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+30.16% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2.1M 2.8B
Iepriekšējā atvēršanas cena	49.64
Iepriekšējā slēgšanas cena	46.92

Ziņu noskaņojums

By Acuity

46%

54%

140 / 344 Rangs Healthcare

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. maijs 16:52 UTC

Galvenie ziņu notikumi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q Rev $1.76B >SQM

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q EPS $1.28 >SQM

2026. g. 26. maijs 23:48 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q EPS $11.61 >WEBC

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q Sales $179.6M >WEBC

2026. g. 26. maijs 21:48 UTC

Tirgus saruna

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026. g. 26. maijs 21:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2026. g. 26. maijs 20:58 UTC

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 26. maijs 19:22 UTC

Tirgus saruna

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026. g. 26. maijs 19:17 UTC

Tirgus saruna

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026. g. 26. maijs 18:56 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026. g. 26. maijs 18:03 UTC

Tirgus saruna

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026. g. 26. maijs 17:42 UTC

Tirgus saruna

Grains Await Fresh Trading Catalyst -- Market Talk

2026. g. 26. maijs 17:33 UTC

Tirgus saruna

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026. g. 26. maijs 17:21 UTC

Tirgus saruna

Canada Faces a Labor Market Squeeze -- Market Talk

2026. g. 26. maijs 16:52 UTC

Tirgus saruna

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026. g. 26. maijs 16:43 UTC

Tirgus saruna

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026. g. 26. maijs 16:24 UTC

Tirgus saruna

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026. g. 26. maijs 16:21 UTC

Tirgus saruna

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

2026. g. 26. maijs 16:16 UTC

Tirgus saruna

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026. g. 26. maijs 16:01 UTC

Tirgus saruna

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026. g. 26. maijs 15:21 UTC

Tirgus saruna

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

30.16% augšup

Prognoze 12 mēnešiem

Vidējais 62.75 USD 30.16%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

140 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.